112 related articles for article (PubMed ID: 29138841)
1. Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
Kubo M; Satoh T; Ishiyama H; Tabata KI; Tsumura H; Komori S; Iwamura M; Baba S; Hayakawa K; Kawamura T; Obata F
Oncol Rep; 2018 Jan; 39(1):417-424. PubMed ID: 29138841
[TBL] [Abstract][Full Text] [Related]
2. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
3. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
[TBL] [Abstract][Full Text] [Related]
4. Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy.
Spadinger I; Chu J; Afsari Golshan M; Keyes M; Pickles T; Hamm J; Morris WJ
Brachytherapy; 2015; 14(3):350-8. PubMed ID: 25638507
[TBL] [Abstract][Full Text] [Related]
5. Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.
Logghe P; Verlinde R; Bouttens F; Van den Broecke C; Deman N; Verboven K; Maes D; Merckx L
Int Braz J Urol; 2016; 42(5):906-917. PubMed ID: 27532118
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
7. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Pickles T; Morris WJ; Keyes M
Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
9. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
10. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
11. Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.
Prada PJ; Anchuelo J; Blanco AG; Paya G; Cardenal J; Acuna E; Ferri M; Vazquez A; Pacheco M; Sanchez J
Int Braz J Urol; 2016; 42(1):47-52. PubMed ID: 27136466
[TBL] [Abstract][Full Text] [Related]
12. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
13. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
14. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
15. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.
Coen JJ; Zietman AL; Rossi CJ; Grocela JA; Efstathiou JA; Yan Y; Shipley WU
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e25-31. PubMed ID: 21470787
[TBL] [Abstract][Full Text] [Related]
16. Six-year experience of permanent prostate brachytherapy for clinically localized prostate cancer.
Teishima J; Kenjo M; Kobatake K; Iwamoto H; Goriki A; Oki M; Shoji K; Miyamoto K; Masumoto H; Inoue S; Kobayashi K; Ohara S; Kajiwara M; Kimura T; Murakami Y; Kaneyasu Y; Nishibuchi I; Nagata Y; Matsubara A
Hiroshima J Med Sci; 2011 Sep; 60(3):51-6. PubMed ID: 22053700
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
18. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
[TBL] [Abstract][Full Text] [Related]
20. Predictors of metastatic disease after prostate brachytherapy.
Forsythe K; Burri R; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
